Dr. Reddy's Laboratories Limited (RDDA) — Cash Flow-to-Debt Ratio
Dr. Reddy's Laboratories Limited (RDDA) has a Cash Flow-to-Debt Ratio of 0.06x as of December 2025, meaning its operating cash flow of €10.91 Billion could theoretically repay 0% of its total liabilities (€187.14 Billion) in one year. See Dr. Reddy's Laboratories Limited leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Dr. Reddy's Laboratories Limited Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Dr. Reddy's Laboratories Limited across 9 annual periods. For the full cash flow conversion analysis, see Dr. Reddy's Laboratories Limited (RDDA) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Dr. Reddy's Laboratories Limited (2017–2025)
Year-by-year debt coverage analysis for Dr. Reddy's Laboratories Limited. Check Dr. Reddy's Laboratories Limited (RDDA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.30x | €46.43 Billion | €155.82 Billion | ▼ -29.8% |
| 2024 | 0.42x | €45.43 Billion | €106.97 Billion | ▼ -35.1% |
| 2023 | 0.65x | €58.88 Billion | €89.99 Billion | ▲ +147.0% |
| 2022 | 0.26x | €28.11 Billion | €106.13 Billion | ▼ -32.9% |
| 2021 | 0.39x | €35.70 Billion | €90.51 Billion | ▲ +2.1% |
| 2020 | 0.39x | €29.84 Billion | €77.25 Billion | ▲ +14.7% |
| 2019 | 0.34x | €28.70 Billion | €85.23 Billion | ▲ +85.2% |
| 2018 | 0.18x | €18.03 Billion | €99.14 Billion | ▼ -19.0% |
| 2017 | 0.22x | €21.51 Billion | €95.78 Billion | — |